drugset / Trial / NCT00323960

Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis

NCT00323960

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a 5-year project, involving 185 partners from 46 countries ((110 in 21 European Union (EU) States and 75 in 25 extra-EU States)), with a randomised clinical trials (RCT) in juvenile dermatomyositis (JDM): 5-year phase III single-blind, RCT in children with newly diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate (MTX) versus PDN plus Cyclosporine A. The trial is aimed to find out the treatment regimen associated with the lowest occurrence of flare and the lowest drug related toxicity

Timeline

Start
2006-05-31
Primary completion
2011-05-12
Completion
2015-11-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 5 mg/kg
Comparator Methotrexate Small molecule 15 mg/m2
Comparator Methotrexate Small molecule 20 mg/m2
Comparator Methylprednisolone Other / unclassified 30 mg/kg
Comparator Prednisone Other / unclassified 0.2 mg/kg